LBRX - NASDAQ

LB Pharmaceuticals Inc Common Stock

LBRX·NASDAQ

$27.95

+3.4%

HealthcareBiotechnology

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$801.51M

EPS-1.0000

P/E Ratio-27.95

Earnings Date06/25/2026

No Revenue Data

LBRX has not reported any revenue values in the available annual periods.

-25.20M

Net Income

-60%

3Y+76.0%

5Y+76.0%

10Y+76.0%

-35.21M

Operating Cash Flow

-34%

3Y+1191.0%

5Y+1191.0%

10Y+1191.0%

LB Pharmaceuticals Inc Common Stock Profit Bridge

LBRX · NASDAQ

Revenue & Cost of Sales

Revenue0.00

Cost of Goods Sold (0.00)

Gross Profit0.00

Operating Expenses

Operating Expenses (30.40M)

Operating Income-30.40M

Other Income & Taxes

Interest Expense (0.00)

Other Income/Expense5.20M

Pretax Income-25.20M

Income Tax (1.00K)

Net Income-25.20M

Net Income

-25.20M

Profitability Analysis

LB Pharmaceuticals Inc Common Stock Income Statement

LBRX • NASDAQ

LB Pharmaceuticals Inc Common Stock Income Statement	Dec 2025	Dec 2024	Dec 2023	Dec 2022
REVENUE
GROSS PROFIT
OPERATING INCOME
Operating Expenses	(30.4M)	(64.8M)	(11.4M)	(2.8M)
Selling, General & Administrative	(13.7M)	(13.7M)	(3.5M)	(1.5M)
Research & Development	(16.7M)	(51.2M)	(7.8M)	(1.3M)
Operating Income	-30.4M	-64.8M	-11.4M	-2.8M
PRE-TAX INCOME
Interest Expense	(0.0)	(0.0)	(4.8M)	(2.2M)
Net Interest Income	3.9M	1.7M	-4M	-2.1M
Total Other Income Expenses Net	5.2M	1.7M	5.1M	-11.5M
Income Before Tax	-25.2M	-63.1M	-6.3M	-14.3M
NET INCOME
Income Tax Expense	(1K)	(1K)	(1K)	(1K)
Net Income	-25.2M	-63.1M	-6.3M	-14.3M

SEC Filings

LBRX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 12, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 12, 2026	May 12, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 23, 2026	June 03, 2026	2026	View Filing
S-1 S-1 N/A	April 06, 2026	April 06, 2026		View Filing
10-K 10-K 2025 FY FY	March 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 26, 2026	March 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 16, 2026	March 13, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 10, 2026	March 04, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 05, 2026	February 04, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 13, 2025	November 10, 2025	2025	View Filing

Showing 1 to 10 of 16 filings

Related Guides

Blog Categories

Continue your LBRX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.